FCCC LOGO Faculty Publications
Konner J , Schilder RJ , DeRosa FA , Gerst SR , Tew WP , Sabbatini PJ , Hensley ML , Spriggs DR , Aghajanian CA
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
Gynecologic Oncology. 2008 Aug;110(2) :140-145
PMID: ISI:000258205700004   
Back to previous list
Objective. Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer. Methods. An initial intravenous [IV] dose of cetuximab (400 mg/m(2)) was administered over 120 min followed by weekly IV infusions of cetuximab (250 mg/m(2)) administered over 60 min. Paclitaxel (175 mg/m(2)) and carboplatin (area under the curve [AUC] of 6) were administered IV every 21 days for 6 cycles. The order of administration was cetuximab followed by paclitaxel and then carboplatin. Patients achieving a clinical complete response after 6 cycles were eligible to continue weekly cetuximab for 6 months or until toxicity or disease progression. Safety was evaluated using NCI Common Toxicity Criteria version 2.0. Progression-free survival (PFS) at 18 months was determined and compared with historical controls. Results. Forty-one patients were enrolled in this study; 40 received treatment and were evaluable for toxicity, and 38 were evaluable for PFS. Grade 3/4 treatment-related toxicities included febrile neutropenia (12.5%), rash (2.5%), hypersensitivity reaction (7.5%), and hypomagnesemia (12.5%). Common grade 1/2 toxicitics attributed to cetuximab included acneiform rash (82.5%), hirsutism (7.5%) or abnormal hair growth (25%), and nail disorders (22.5%), which in 3 cases resulted in the patient's discontinuation from the study. Median PFS was 14.4 months, and PFS at 18 months was 38.8%. Conclusions. The combination of cetuximab with paclitaxel and carboplatin is adequately tolerated as primary therapy for ovarian cancer but did not demonstrate prolongation of PFS when compared to historical data. (c) 2008 Elsevier Inc. All rights reserved.
ISI Document Delivery No.: 334ES Times Cited: 0 Cited Reference Count: 39 Cited References: *IMCLONE SYST INC, 2007, ERBITUX CET PACK INS *OSI PHARM INC, 2007, TARC ERL PACK INS AKAGI M, 2003, BRIT J CANCER, V88, P796 AMADO RG, 2008, J CLIN ONCOL BARTLETT JMS, 1996, BRIT J CANCER, V73, P301 BASELGA J, 1993, J NATL CANCER I, V85, P1327 BOOKMAN MA, 2003, J CLIN ONCOL, V21, P283 BOOKMAN MA, 2006, J CLIN ONCOL S, V24, P5002 CAMPOS SM, 2004, J CLIN ONCOL, V22, A5054 CROSS M, 1991, CELL, V64, P271 DUBOIS A, 2006, J CLIN ONCOL, V24, P1127 FAN Z, 1993, CANCER RES, V53, P4322 FAN Z, 1993, CANCER RES, V53, P4637 FISCHERCOLBRIE J, 1997, ANTICANCER RES, V17, P613 GORDON AN, 2005, INT J GYNECOL CANCER, V15, P785 GORDON MS, 2006, J CLIN ONCOL, V24, P4324 JERNAL A, 2007, CA CANC J CLIN, V57, P43 KAWAGUCHI Y, 2006, INT J CANCER, V120, P781 KHAMBATAFORD S, 2007, J CLIN ONCOL, V25, P3230 KURAI J, 2007, CLIN CANCER RES, V13, P1552 LYNCH TJ, 2004, NEW ENGL J MED, V350, P2129 MCGUIRE WP, 1996, NEW ENGL J MED, V334, P1 NIIKURA H, 1997, INT J GYNECOL PATHOL, V16, P60 OZOLS RF, 2003, J CLIN ONCOL, V21, P3194 PAEZ JG, 2004, SCIENCE, V304, P1497 PAO W, 2004, P NATL ACAD SCI USA, V101, P13306 PETIT AMV, 1997, AM J PATHOL, V151, P1523 PICCART MJ, 2000, J NATL CANCER I, V92, P699 PREWETT M, 1998, CLIN CANCER RES, V4, P2957 RUBIN MSS, 2000, P AM SOC CLIN ONCOL, V19 SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183 SCHILDER RJ, 2005, CLIN CANCER RES, V11, P5539 SCHIOTZ A, 2007, ALYTES, V25, P1 SCHRAG D, 2005, J NATL CANCER I, V97, P1221 SECORD AA, 2008, GYNECOL ONCOL, V108, P493 SHAHEEN RM, 2001, BRIT J CANCER, V85, P584 STRAWN LM, 1998, EXPERT OPIN INV DRUG, V7, P553 THIENELT CD, 2005, J CLIN ONCOL, V23, P8786 WAKSAL HW, 1999, CANCER METAST REV, V18, P427 Konner, Jason Schilder, Russell J. DeRosa, Felicia A. Gerst, Scott R. Tew, William P. Sabbatini, Paul J. Hensley, Martee L. Spriggs, David R. Aghajanian, Carol A. ACADEMIC PRESS INC ELSEVIER SCIENCE; 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA